Theranostics Market Size, Share and Growth Outlook 2026: By Offering, By Technology, By Radioisotope, By Application, By End User, Companies to 2034
The global Theranostics Market size is forecast to increase from $2.97 Billion in 2026 to $8.96 Billion in 2034 at a CAGR of 14.8% between 2026 and 2034.
The Theranostics market report provides detailed analysis and outlook of Theranostics segments including By Offering (Diagnostic Imaging and Radionuclides, Radiopharmaceuticals and Targeted Therapeutic Agents, In Vitro Diagnostics (IVD) and Biomarker Screening Kits, Software, Dosimetry Systems, and Support Services), By Technology (Targeted Therapeutics, Targeted Diagnostics ), By Radioisotope (Lutetium-177, Gallium-68, Iodine-131, Iodine-123, Fluorine-18, Others ), By Application (Prostate Cancer, Neuroendocrine Tumors (NETs), Thyroid Cancer, Hepatocellular Carcinoma, Bone Metastasis, Other Cancers, Neurological Disorders, Cardiovascular Diseases, Rheumatoid Arthritis / Joint Inflammation), By End User (Hospitals and Specialized Cancer Care Centers, Theranostics and Nuclear Medicine Centers, Research and Academic Institutions) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Theranostics Industry Overview
Integrated Precision Medicine Is Accelerating Theranostics Adoption
The global theranostics industry is expanding rapidly as precision medicine increasingly combines molecular imaging with targeted radiopharmaceutical therapies to improve cancer diagnosis, treatment selection, and therapeutic monitoring. Healthcare systems are investing in integrated theranostic programs that connect imaging, radiopharmaceutical production, clinical research, and personalized treatment within unified care pathways. Advances in targeted isotopes, imaging biomarkers, and radiopharmaceutical manufacturing are enabling clinicians to identify disease more accurately while delivering therapies that selectively target malignant cells and minimize damage to surrounding healthy tissue. As clinical adoption broadens, collaboration among healthcare providers, technology companies, pharmaceutical developers, and research organizations is becoming essential to building scalable theranostics infrastructure and standardized clinical practice.
Strategic Partnerships Expand Clinical Infrastructure and Radiopharmaceutical Access
The industry is increasingly characterized by partnerships that integrate manufacturing, clinical expertise, and healthcare delivery to accelerate adoption of personalized radiopharmaceutical therapies. Organizations are building comprehensive treatment networks capable of supporting both diagnostic imaging and targeted therapeutic services. Sentara Health partnered with BAMF Health to establish a vertically integrated theranostics program that combines advanced molecular imaging with personalized radiopharmaceutical therapies while leveraging expertise in radiopharmaceutical manufacturing, infrastructure development, and clinical trial integration. Supporting continued expansion of precision diagnostics, Radiopharm Theranostics entered a clinical supply agreement with Siemens Healthineers to manufacture and distribute the fluorine-18 labeled imaging agent RAD101 through its radiopharmacy network for a multicenter Phase 3 trial targeting recurrent brain metastases using fatty acid synthase imaging.
Standardization Initiatives Strengthen Global Theranostics Development
As theranostics becomes more widely adopted, the industry is placing greater emphasis on standardized imaging protocols, quantitative dosimetry, and harmonized quality assurance to improve reproducibility across clinical centers. International collaboration is driving the development of common measurement standards that support multicenter clinical trials and broader regulatory acceptance of targeted radiopharmaceutical therapies. Reflecting this direction, an international consortium of academic, corporate, and government organizations launched the Precision Dosimetry Imaging Biomarker initiative to establish standardized SPECT/CT calibration networks across Europe, North America, and Australia. The program focuses on improving measurement consistency for critical theranostic isotopes including lutetium-177, actinium-225, and lead-212, reinforcing the industry's transition toward globally standardized, data-driven theranostic ecosystems capable of supporting precision oncology on a larger scale.
Theranostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Theranostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Advanced Accelerator Applications (Novartis), Bayer AG, GE Healthcare, Lantheus Holdings, Inc., Curium, Telix Pharmaceuticals, Cardinal Health, Eckert & Ziegler, Fusion Pharmaceuticals (AstraZeneca), Jubilant Radiopharma. The Theranostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Theranostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Theranostics industry include- Advanced Accelerator Applications (Novartis), Bayer AG, GE Healthcare, Lantheus Holdings, Inc., Curium, Telix Pharmaceuticals, Cardinal Health, Eckert & Ziegler, Fusion Pharmaceuticals (AstraZeneca), Jubilant Radiopharma. The Theranostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Theranostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Theranostics market remains one of the strongest-performing segments in the country.
The US Theranostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Theranostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Theranostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Theranostics markets
Canada's strong Theranostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Theranostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Theranostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Theranostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Theranostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Theranostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Theranostics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Theranostics sales through 2034
France Theranostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Theranostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Theranostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Theranostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Theranostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Theranostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Theranostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Theranostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Theranostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Theranostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Theranostics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Theranostics Market Segmentation
By Offering
Diagnostic Imaging and Radionuclides
Radiopharmaceuticals and Targeted Therapeutic Agents
In Vitro Diagnostics (IVD) and Biomarker Screening Kits
Software, Dosimetry Systems, and Support Services
By Technology
Targeted Therapeutics
Targeted Diagnostics
By Radioisotope
Lutetium-177
Gallium-68
Iodine-131
Iodine-123
Fluorine-18
Others
By Application
Prostate Cancer
Neuroendocrine Tumors (NETs)
Thyroid Cancer
Hepatocellular Carcinoma
Bone Metastasis
Other Cancers
Neurological Disorders
Cardiovascular Diseases
Rheumatoid Arthritis / Joint Inflammation
By End User
Hospitals and Specialized Cancer Care Centers
Theranostics and Nuclear Medicine Centers
Research and Academic Institutions
Leading Companies in Theranostics Industry (2026)
Advanced Accelerator Applications (Novartis)
Bayer AG
GE Healthcare
Lantheus Holdings, Inc.
Curium
Telix Pharmaceuticals
Cardinal Health
Eckert & Ziegler
Fusion Pharmaceuticals (AstraZeneca)
Jubilant Radiopharma
Countries Included
The Theranostics market report provides detailed analysis and outlook of Theranostics segments including By Offering (Diagnostic Imaging and Radionuclides, Radiopharmaceuticals and Targeted Therapeutic Agents, In Vitro Diagnostics (IVD) and Biomarker Screening Kits, Software, Dosimetry Systems, and Support Services), By Technology (Targeted Therapeutics, Targeted Diagnostics ), By Radioisotope (Lutetium-177, Gallium-68, Iodine-131, Iodine-123, Fluorine-18, Others ), By Application (Prostate Cancer, Neuroendocrine Tumors (NETs), Thyroid Cancer, Hepatocellular Carcinoma, Bone Metastasis, Other Cancers, Neurological Disorders, Cardiovascular Diseases, Rheumatoid Arthritis / Joint Inflammation), By End User (Hospitals and Specialized Cancer Care Centers, Theranostics and Nuclear Medicine Centers, Research and Academic Institutions) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Theranostics Industry Overview
Integrated Precision Medicine Is Accelerating Theranostics Adoption
The global theranostics industry is expanding rapidly as precision medicine increasingly combines molecular imaging with targeted radiopharmaceutical therapies to improve cancer diagnosis, treatment selection, and therapeutic monitoring. Healthcare systems are investing in integrated theranostic programs that connect imaging, radiopharmaceutical production, clinical research, and personalized treatment within unified care pathways. Advances in targeted isotopes, imaging biomarkers, and radiopharmaceutical manufacturing are enabling clinicians to identify disease more accurately while delivering therapies that selectively target malignant cells and minimize damage to surrounding healthy tissue. As clinical adoption broadens, collaboration among healthcare providers, technology companies, pharmaceutical developers, and research organizations is becoming essential to building scalable theranostics infrastructure and standardized clinical practice.
Strategic Partnerships Expand Clinical Infrastructure and Radiopharmaceutical Access
The industry is increasingly characterized by partnerships that integrate manufacturing, clinical expertise, and healthcare delivery to accelerate adoption of personalized radiopharmaceutical therapies. Organizations are building comprehensive treatment networks capable of supporting both diagnostic imaging and targeted therapeutic services. Sentara Health partnered with BAMF Health to establish a vertically integrated theranostics program that combines advanced molecular imaging with personalized radiopharmaceutical therapies while leveraging expertise in radiopharmaceutical manufacturing, infrastructure development, and clinical trial integration. Supporting continued expansion of precision diagnostics, Radiopharm Theranostics entered a clinical supply agreement with Siemens Healthineers to manufacture and distribute the fluorine-18 labeled imaging agent RAD101 through its radiopharmacy network for a multicenter Phase 3 trial targeting recurrent brain metastases using fatty acid synthase imaging.
Standardization Initiatives Strengthen Global Theranostics Development
As theranostics becomes more widely adopted, the industry is placing greater emphasis on standardized imaging protocols, quantitative dosimetry, and harmonized quality assurance to improve reproducibility across clinical centers. International collaboration is driving the development of common measurement standards that support multicenter clinical trials and broader regulatory acceptance of targeted radiopharmaceutical therapies. Reflecting this direction, an international consortium of academic, corporate, and government organizations launched the Precision Dosimetry Imaging Biomarker initiative to establish standardized SPECT/CT calibration networks across Europe, North America, and Australia. The program focuses on improving measurement consistency for critical theranostic isotopes including lutetium-177, actinium-225, and lead-212, reinforcing the industry's transition toward globally standardized, data-driven theranostic ecosystems capable of supporting precision oncology on a larger scale.
Theranostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Theranostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Advanced Accelerator Applications (Novartis), Bayer AG, GE Healthcare, Lantheus Holdings, Inc., Curium, Telix Pharmaceuticals, Cardinal Health, Eckert & Ziegler, Fusion Pharmaceuticals (AstraZeneca), Jubilant Radiopharma. The Theranostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Theranostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Theranostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Theranostics companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Theranostics markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Theranostics industry include- Advanced Accelerator Applications (Novartis), Bayer AG, GE Healthcare, Lantheus Holdings, Inc., Curium, Telix Pharmaceuticals, Cardinal Health, Eckert & Ziegler, Fusion Pharmaceuticals (AstraZeneca), Jubilant Radiopharma. The Theranostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Theranostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Theranostics market remains one of the strongest-performing segments in the country.
The US Theranostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Theranostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Theranostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Theranostics markets
Canada's strong Theranostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Theranostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Theranostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Theranostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Theranostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Theranostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Theranostics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Theranostics sales through 2034
France Theranostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Theranostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Theranostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Theranostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Theranostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Theranostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Theranostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Theranostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Theranostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Theranostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Theranostics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Theranostics Market Segmentation
By Offering
Diagnostic Imaging and Radionuclides
Radiopharmaceuticals and Targeted Therapeutic Agents
In Vitro Diagnostics (IVD) and Biomarker Screening Kits
Software, Dosimetry Systems, and Support Services
By Technology
Targeted Therapeutics
Targeted Diagnostics
By Radioisotope
Lutetium-177
Gallium-68
Iodine-131
Iodine-123
Fluorine-18
Others
By Application
Prostate Cancer
Neuroendocrine Tumors (NETs)
Thyroid Cancer
Hepatocellular Carcinoma
Bone Metastasis
Other Cancers
Neurological Disorders
Cardiovascular Diseases
Rheumatoid Arthritis / Joint Inflammation
By End User
Hospitals and Specialized Cancer Care Centers
Theranostics and Nuclear Medicine Centers
Research and Academic Institutions
Leading Companies in Theranostics Industry (2026)
Advanced Accelerator Applications (Novartis)
Bayer AG
GE Healthcare
Lantheus Holdings, Inc.
Curium
Telix Pharmaceuticals
Cardinal Health
Eckert & Ziegler
Fusion Pharmaceuticals (AstraZeneca)
Jubilant Radiopharma
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Theranostics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Theranostics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL THERANOSTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Theranostics Markets in 2026
3.2. Global Historic and Forecast Theranostics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Theranostics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Theranostics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Theranostics Value Chain
CHAPTER 4- THERANOSTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Theranostics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- THERANOSTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Offering
Diagnostic Imaging and Radionuclides
Radiopharmaceuticals and Targeted Therapeutic Agents
In Vitro Diagnostics (IVD) and Biomarker Screening Kits
Software, Dosimetry Systems, and Support Services
By Technology
Targeted Therapeutics
Targeted Diagnostics
By Radioisotope
Lutetium-177
Gallium-68
Iodine-131
Iodine-123
Fluorine-18
Others
By Application
Prostate Cancer
Neuroendocrine Tumors (NETs)
Thyroid Cancer
Hepatocellular Carcinoma
Bone Metastasis
Other Cancers
Neurological Disorders
Cardiovascular Diseases
Rheumatoid Arthritis / Joint Inflammation
By End User
Hospitals and Specialized Cancer Care Centers
Theranostics and Nuclear Medicine Centers
Research and Academic Institutions
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Theranostics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Theranostics Market Trends and Growth Opportunities to 2034
7.5. North America Theranostics Market Size Outlook by Type
7.6. North America Theranostics Market Size Outlook by Application
7.7. North America Theranostics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Theranostics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Theranostics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Theranostics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Theranostics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Theranostics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Theranostics Companies
CHAPTER 8- EUROPE THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Theranostics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Theranostics Market Trends and Growth Opportunities to 2034
8.5. Europe Theranostics Market Size Outlook by Type
8.6. Europe Theranostics Market Size Outlook by Application
8.7. Europe Theranostics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Theranostics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Theranostics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Theranostics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Theranostics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Theranostics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Theranostics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Theranostics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Theranostics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Theranostics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Theranostics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Theranostics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Theranostics Companies
CHAPTER 9- ASIA PACIFIC THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Theranostics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Theranostics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Theranostics Market Size Outlook by Type
9.6. Asia Pacific Theranostics Market Size Outlook by Application
9.7. Asia Pacific Theranostics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Theranostics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Theranostics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Theranostics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Theranostics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Theranostics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Theranostics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Theranostics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Theranostics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Theranostics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Theranostics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Theranostics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Theranostics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Theranostics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Theranostics Market Trends and Growth Opportunities to 2034
10.5. South and Central America Theranostics Market Size Outlook by Type
10.6. South and Central America Theranostics Market Size Outlook by Application
10.7. South and Central America Theranostics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Theranostics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Theranostics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Theranostics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Theranostics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Theranostics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Theranostics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Theranostics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Theranostics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Theranostics Market Size Outlook by Type
11.6. Middle East and Africa Theranostics Market Size Outlook by Application
11.7. Middle East and Africa Theranostics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Theranostics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Theranostics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Theranostics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Theranostics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Theranostics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Theranostics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Theranostics Industry
Advanced Accelerator Applications (Novartis)
Bayer AG
GE Healthcare
Lantheus Holdings, Inc.
Curium
Telix Pharmaceuticals
Cardinal Health
Eckert & Ziegler
Fusion Pharmaceuticals (AstraZeneca)
Jubilant Radiopharma
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Theranostics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Theranostics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL THERANOSTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Theranostics Markets in 2026
3.2. Global Historic and Forecast Theranostics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Theranostics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Theranostics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Theranostics Value Chain
CHAPTER 4- THERANOSTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Theranostics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- THERANOSTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Offering
Diagnostic Imaging and Radionuclides
Radiopharmaceuticals and Targeted Therapeutic Agents
In Vitro Diagnostics (IVD) and Biomarker Screening Kits
Software, Dosimetry Systems, and Support Services
By Technology
Targeted Therapeutics
Targeted Diagnostics
By Radioisotope
Lutetium-177
Gallium-68
Iodine-131
Iodine-123
Fluorine-18
Others
By Application
Prostate Cancer
Neuroendocrine Tumors (NETs)
Thyroid Cancer
Hepatocellular Carcinoma
Bone Metastasis
Other Cancers
Neurological Disorders
Cardiovascular Diseases
Rheumatoid Arthritis / Joint Inflammation
By End User
Hospitals and Specialized Cancer Care Centers
Theranostics and Nuclear Medicine Centers
Research and Academic Institutions
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Theranostics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Theranostics Market Trends and Growth Opportunities to 2034
7.5. North America Theranostics Market Size Outlook by Type
7.6. North America Theranostics Market Size Outlook by Application
7.7. North America Theranostics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Theranostics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Theranostics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Theranostics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Theranostics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Theranostics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Theranostics Companies
CHAPTER 8- EUROPE THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Theranostics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Theranostics Market Trends and Growth Opportunities to 2034
8.5. Europe Theranostics Market Size Outlook by Type
8.6. Europe Theranostics Market Size Outlook by Application
8.7. Europe Theranostics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Theranostics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Theranostics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Theranostics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Theranostics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Theranostics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Theranostics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Theranostics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Theranostics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Theranostics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Theranostics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Theranostics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Theranostics Companies
CHAPTER 9- ASIA PACIFIC THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Theranostics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Theranostics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Theranostics Market Size Outlook by Type
9.6. Asia Pacific Theranostics Market Size Outlook by Application
9.7. Asia Pacific Theranostics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Theranostics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Theranostics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Theranostics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Theranostics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Theranostics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Theranostics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Theranostics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Theranostics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Theranostics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Theranostics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Theranostics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Theranostics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Theranostics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Theranostics Market Trends and Growth Opportunities to 2034
10.5. South and Central America Theranostics Market Size Outlook by Type
10.6. South and Central America Theranostics Market Size Outlook by Application
10.7. South and Central America Theranostics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Theranostics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Theranostics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Theranostics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Theranostics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Theranostics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Theranostics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA THERANOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Theranostics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Theranostics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Theranostics Market Size Outlook by Type
11.6. Middle East and Africa Theranostics Market Size Outlook by Application
11.7. Middle East and Africa Theranostics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Theranostics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Theranostics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Theranostics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Theranostics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Theranostics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Theranostics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Theranostics Industry
Advanced Accelerator Applications (Novartis)
Bayer AG
GE Healthcare
Lantheus Holdings, Inc.
Curium
Telix Pharmaceuticals
Cardinal Health
Eckert & Ziegler
Fusion Pharmaceuticals (AstraZeneca)
Jubilant Radiopharma
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
